L-Glutamine Sachets: Indications and Dosage
L-glutamine sachets are FDA-approved specifically to reduce acute complications of sickle cell disease in patients 5 years of age and older, administered at 5-15 grams orally twice daily based on body weight 1.
FDA-Approved Indication
The only FDA-approved indication for L-glutamine oral powder is:
- Sickle cell disease: To reduce acute complications in adult and pediatric patients ≥5 years old 1
This is the primary clinical indication where L-glutamine sachets should be prescribed.
Dosage Regimen
Weight-based dosing, administered twice daily 1:
- <30 kg (<66 lbs): 5 grams per dose = 10 grams/day (1 packet twice daily)
- 30-65 kg (66-143 lbs): 10 grams per dose = 20 grams/day (2 packets twice daily)
- >65 kg (>143 lbs): 15 grams per dose = 30 grams/day (3 packets twice daily)
Administration Instructions
Mix each dose immediately before ingestion with 1:
- 8 oz (240 mL) of cold or room temperature beverage (water, milk, apple juice), OR
- 4-6 oz of food (applesauce, yogurt)
- Complete dissolution is not required before administration
Important Clinical Context from Guidelines
Where L-Glutamine Should NOT Be Used
In critically ill ICU patients, particularly those with liver and renal failure, parenteral glutamine-dipeptide shall not be administered (Grade A recommendation) 2. This represents a critical safety concern following large trials showing potential harm in unstable, complex ICU patients.
Other Clinical Applications (Off-Label, Research Context)
While not FDA-approved for sachets, glutamine supplementation has been studied in:
- Major burns: Demonstrated reduction in infectious complications and mortality at doses around 20-30 g/day 2
- Major trauma: Some evidence for infection reduction 2
- Parenteral nutrition in stable critically ill patients: IV glutamine (0.2-0.3 g/kg/day) showed benefits when part of adequate nutrition support, but this applies to IV formulations, not oral sachets 2
Critical caveat: The 2019 ESPEN ICU guidelines explicitly state that indiscriminate use of glutamine supplementation for all critically ill patients is no longer recommended 2. The harmful effects observed in unstable patients (particularly the REDOXS trial) have fundamentally changed clinical practice.
Dosing Considerations from Research
Research suggests that higher doses (≥30 g/day enterally or >0.25-0.3 g/kg/day IV) demonstrate greater potential benefit than lower doses 3. However, doses up to 0.65 g/kg body mass have been tolerated without abnormal ammonia levels 4.
Important safety note: A recent case report documented acute kidney injury from 18 grams daily in an elderly patient with compromised kidney function, likely due to increased ammonia production and tubular toxicity 5. Exercise caution in elderly patients and those with pre-existing renal impairment.
Clinical Pitfalls to Avoid
- Do not use in unstable ICU patients or those with liver/renal failure - this can cause harm 2
- Do not assume all critically ill patients need glutamine - only those with documented hypoglutaminemia may benefit, and even this remains controversial 6
- Do not use inadequate doses - if supplementing off-label for intestinal disorders, doses similar to daily enterocyte metabolism (~30g) showed positive results, while doses based on dietary intake did not 7
- Monitor elderly and renally impaired patients - risk of ammonia toxicity and AKI 5
For the FDA-approved indication (sickle cell disease), follow the weight-based dosing table exactly as specified in the drug label 1.